Sep 13, 2022 / 08:40PM GMT
Cecilia E. Furlong - Morgan Stanley, Research Division - Equity Analyst
Good afternoon, and welcome to the second day -- nearly the end of the second day of the Morgan Stanley Healthcare Conference. I am Cecilia Furlong, medical device analyst here at Morgan Stanley. It is my pleasure to have Pulmonx with us; CEO, Glen French; CFO, Derrick Sung. Thank you both for being here today.
Glendon E. French - Pulmonx Corporation - CEO, President & Director
Thank you.
Questions and Answers:
Cecilia E. Furlong - Morgan Stanley, Research Division - Equity AnalystAnd I think we've started a lot of these conversations with macro. I'd love to start with CONVERT given what we've heard recently from a data standpoint. But as you think about just for the field? What's the greatest potential benefit as you contemplate further adoption?
Glendon E. French - Pulmonx Corporation - CEO, President & Director
Specific to CONVERT or...
Cecilia E. Furlong -